Domperidone

Exposed non-exposed studies (cohort)

Study Country
Study period
Population source Exposure definition Non-exposure definition Sample size Rmk
Choi, 2013 Korea
Not specified
First trimester pregnant women who were referred to the Korean Motherisk Program for prenatal risk counselling. Pregnant women treated with domperidone for controlling gastrointestinal symptoms. unexposed (not otherwise specified)
Pregnant women who were not exposed to any other teratogenic medication.
120 / 212
Cottin (Control exposed to other treatments), 2015 France
1995 - 2014
Pregnant women who called TIS to be counselled about teratogenicity. Pregnant women exposed to domperidone within 4 to 12 weeks after the last menstrual period and not exposed to any other antiemetic drug during embryogenesis. exposed to other treatment, sick
Pregnant women who were taking other antiemetic drugs (metoclopramide or doxylamine).
124 / 97 Raw data provided by personal communication of the authors.
Cottin (Controls unexposed, disease free), 2015 France
1995 - 2014
Pregnant women who called TIS to be counselled about teratogenicity Pregnant women exposed to domperidone within 4 to 12 weeks after the last menstrual period and not exposed to any other antiemetic drug during embryogenesis. unexposed, disease free
Pregnant women who were counselled after a non-teratogenic exposure during the same period
124 / 248 Raw data provided by personal communication of the authors.

Case-control studies (cohort)

Study Country
Study period
Case Control Sample size Rmk
Fejzo, 2015 USA
2007 - 2011
Children exposed to hyperemesis gravidarum (HG) with neurodevelopmental delay. Children exposed to hyperemesis gravidarum (HG) with a good outcome. 138 / 174 Main analysis: case control related to the impact of the HG illness (treated or not) on child outcomes. Then impact of 37 medications/treatments (1st and/or 2nd trimester) on child outcome was investigated (none was significantly associated with delay).
Fejzo, 2013 USA
2007 - 2011
Pregnant women with hyperemesis gravidarum (HG) who have negative outcomes (birth weight less than 10%, perinatal mortality, and/or preterm birth (<37 weeks)). Pregnant women with hyperemesis gravidarum (HG) who have positive outcomes. 43 / 211 Comparison of use of various medications/treatments in the two groups (43 HG participants with an adverse outcome compared to 211 HG participants with a good outcome).

See the method used to produce these results